Evaluating cancer-associated fibroblasts using PET imaging
Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
NA · Osaka University · NCT05442151
This study is testing a new type of PET imaging to see if it can better help doctors understand and treat pancreatic and gastric cancer by looking at the supportive tissue around the tumors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Osaka University (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Suita, Osaka) |
| Trial ID | NCT05442151 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of a specific PET imaging agent, [18F] FAPI-74, to assess cancer-associated fibroblasts in patients diagnosed with malignant tumors, particularly pancreatic and gastric cancers. The approach involves comparing the results of this imaging technique with traditional FDG-PET/CT scans to gain a deeper understanding of the tumor pathology. By focusing on the cancer stroma, which constitutes a significant portion of tumors, the study aims to enhance diagnostic accuracy and treatment planning for affected patients.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with malignant tumors or those suspected of having such tumors who have undergone prior imaging.
Not a fit: Patients who are pregnant, pediatric patients requiring sedation, or those deemed inappropriate for the study will not benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for cancer, allowing for more tailored and effective treatment strategies.
How similar studies have performed: Other studies using similar PET imaging techniques have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who meet any of the following conditions. 1. Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination. 2. Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy. 3. Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor Exclusion Criteria: 1. Pregnant women or patients who may be pregnant 2. Pediatric patients requiring sedation 3. Those who are judged to be inappropriate as subjects.
Where this trial is running
Suita, Osaka
- Osaka University Hospital — Suita, Osaka, Japan (RECRUITING)
Study contacts
- Study coordinator: Tadashi Watabe, M.D., Ph.D.
- Email: watabe@tracer.med.osaka-u.ac.jp
- Phone: +81-6-6879-3461
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasms